SCHEMBL5127716

SCHEMBL5127716

CCOc1cc(OCC)nc(C(=O)N(Cc2cccc(CC)c2)C[C@@H](O)[C@@H](N)Cc2cc(F)cc(F)c2)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 13/20 0.36
CTSD P07339 3/20 0.36
MAPT P10636 2/20 0.32
TRPM8 Q7Z2W7 2/20 0.32
CTSB P07858 4/20 0.31
NPSR1 Q6W5P4 2/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
BACE2 Q9Y5Z0 1/20 0.31
SLC6A9 P48067 1/20 0.31
KCNH2 Q12809 1/20 0.31
LMNA P02545 2/20 0.30
KDM4E B2RXH2 1/20 0.30
ALDH1A1 P00352 1/20 0.30
HPGD P15428 1/20 0.30
ALOX15 P16050 1/20 0.30
TSHR P16473 1/20 0.30
HTT P42858 1/20 0.30
HSD17B10 Q99714 1/20 0.30
NPC1 O15118 1/20 0.30
RAB9A P51151 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5124865 0.79 BACE1 (0.43) BACE1CTSDMAPTCTSBBACE2
SCHEMBL5129694 0.79 BACE1 (0.37) BACE1CTSDMAPTTRPM8CTSB
SCHEMBL5124917 0.78 BACE1 (0.49) BACE1CTSDBACE2
SCHEMBL5579820 0.78 BACE1 (0.41) BACE1CTSDCTSB
SCHEMBL5124834 0.78 BACE1 (0.39) BACE1CTSDCTSBALDH1A1HPGD
SCHEMBL5130830 0.78 BACE1 (0.37) BACE1CTSDMAPTCTSBNPSR1
SCHEMBL5121085 0.77 BACE1 (0.35) BACE1CTSDCTSB
SCHEMBL5130857 0.77 KMT2A (0.49) BACE1CTSDMAPTBACE2
SCHEMBL5120921 0.77 HTT (0.42) BACE1CTSDMAPTALDH1A1HPGD
SCHEMBL5120182 0.77 L3MBTL1 (0.37) BACE1CTSDMAPTCTSBNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7294642-B2 1,3-Diamino-2-hydroxypropane pro-drug derivatives ELAN PHARMACEUTICALS, INC. (US) 2007-11-13 US claimed
US-20080161325-A1 e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome ELAN PHARMACEUTICALS, INC. 2008-07-03 US disclosed
US-7294642-B2 1,3-Diamino-2-hydroxypropane pro-drug derivatives ELAN PHARMACEUTICALS, INC. (US) 2007-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161325-A1 e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome BACE1, APP, BACE2 BACE1 1/4885CTSD 100/4885MAPT 246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.